Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US. Currently, the ongoing Pivotal Phase II Study focuses on the application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.
Comments from KORTUC
“We are pleased to share our vision with and receive such strong support from our new investor as we are accelerating our clinical research in the UK and the US to bring to cancer patients globally a product that can make a true difference in the near future – we firmly believe that Kortuc radiosensitizer can change the paradigm for use of radiotherapy across cancer types and stages” highlighted Kazu Matsuda, Chief Executive Officer of KORTUC.
Comments from AXA Japan
“As a worldwide leader in insurance and asset management, our purpose is to act for human progress by protecting what matters. As new cancer patient growth accelerates, this investment illustrates our purpose to support innovative technologies that can serve humanity.” Jean-Baptiste Tricot, Director, Executive Officer, and Chief Financial Officer of AXA Japan commented.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Boris Moutier, Corporate Officer of AXA Japan, Japan, and Asia Chief Investment Officer, also highlights that “With this brand new radiosensitizer, KORTUC has great potential to become a ground-breaking player in the cancer treatment field, and we are glad to engage in this greatly promising journey. Aligned with AXA Group’s vision, AXA Japan pursues investments into startups that may create innovations and produce tangible results.”
Source: Biospace